|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTL |
Gene summary for TTL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTL | Gene ID | 150465 |
| Gene name | tubulin tyrosine ligase | |
| Gene Alias | TTL | |
| Cytomap | 2q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8NG68 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 150465 | TTL | HCC1_Meng | Human | Liver | HCC | 2.30e-18 | 1.76e-02 | 0.0246 |
| 150465 | TTL | HCC2 | Human | Liver | HCC | 9.58e-20 | 3.89e+00 | 0.5341 |
| 150465 | TTL | Pt14.a | Human | Liver | HCC | 2.24e-03 | 2.59e-01 | 0.0169 |
| 150465 | TTL | S014 | Human | Liver | HCC | 1.02e-03 | 2.53e-01 | 0.2254 |
| 150465 | TTL | S016 | Human | Liver | HCC | 1.25e-02 | 1.97e-01 | 0.2243 |
| 150465 | TTL | S028 | Human | Liver | HCC | 1.53e-16 | 5.89e-01 | 0.2503 |
| 150465 | TTL | S029 | Human | Liver | HCC | 2.40e-10 | 5.72e-01 | 0.2581 |
| 150465 | TTL | C04 | Human | Oral cavity | OSCC | 1.01e-08 | 6.21e-01 | 0.2633 |
| 150465 | TTL | C21 | Human | Oral cavity | OSCC | 4.49e-08 | 3.48e-01 | 0.2678 |
| 150465 | TTL | C30 | Human | Oral cavity | OSCC | 6.89e-11 | 5.60e-01 | 0.3055 |
| 150465 | TTL | C38 | Human | Oral cavity | OSCC | 8.98e-05 | 5.37e-01 | 0.172 |
| 150465 | TTL | C46 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.1673 |
| 150465 | TTL | C51 | Human | Oral cavity | OSCC | 8.78e-04 | 2.58e-01 | 0.2674 |
| 150465 | TTL | C09 | Human | Oral cavity | OSCC | 3.48e-02 | 9.74e-02 | 0.1431 |
| 150465 | TTL | SYSMH1 | Human | Oral cavity | OSCC | 5.30e-08 | 2.88e-01 | 0.1127 |
| 150465 | TTL | SYSMH2 | Human | Oral cavity | OSCC | 3.78e-09 | 3.36e-01 | 0.2326 |
| 150465 | TTL | SYSMH3 | Human | Oral cavity | OSCC | 3.60e-23 | 5.98e-01 | 0.2442 |
| 150465 | TTL | male-WTA | Human | Thyroid | PTC | 2.21e-14 | 1.64e-01 | 0.1037 |
| 150465 | TTL | PTC01 | Human | Thyroid | PTC | 1.95e-02 | 3.73e-02 | 0.1899 |
| 150465 | TTL | PTC04 | Human | Thyroid | PTC | 1.89e-05 | 1.61e-01 | 0.1927 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00709188 | Esophagus | ESCC | production of small RNA involved in gene silencing by RNA | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:00304881 | Esophagus | ESCC | tRNA methylation | 30/8552 | 41/18723 | 3.27e-04 | 1.93e-03 | 30 |
| GO:00450885 | Esophagus | ESCC | regulation of innate immune response | 125/8552 | 218/18723 | 3.34e-04 | 1.96e-03 | 125 |
| GO:00714821 | Esophagus | ESCC | cellular response to light stimulus | 75/8552 | 123/18723 | 4.45e-04 | 2.50e-03 | 75 |
| GO:00507775 | Esophagus | ESCC | negative regulation of immune response | 112/8552 | 194/18723 | 4.67e-04 | 2.62e-03 | 112 |
| GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
| GO:00459483 | Esophagus | ESCC | positive regulation of translational initiation | 23/8552 | 30/18723 | 5.47e-04 | 3.00e-03 | 23 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:00090484 | Esophagus | ESCC | dosage compensation by inactivation of X chromosome | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
| GO:00800092 | Esophagus | ESCC | mRNA methylation | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
| GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
| GO:00165561 | Esophagus | ESCC | mRNA modification | 21/8552 | 27/18723 | 6.88e-04 | 3.61e-03 | 21 |
| GO:200073614 | Esophagus | ESCC | regulation of stem cell differentiation | 39/8552 | 58/18723 | 7.43e-04 | 3.86e-03 | 39 |
| GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
| GO:000268316 | Esophagus | ESCC | negative regulation of immune system process | 231/8552 | 434/18723 | 8.48e-04 | 4.36e-03 | 231 |
| GO:00085935 | Esophagus | ESCC | regulation of Notch signaling pathway | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
| GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTL | SNV | Missense_Mutation | c.971N>G | p.Glu324Gly | p.E324G | Q8NG68 | protein_coding | tolerated(0.16) | benign(0.026) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTL | SNV | Missense_Mutation | novel | c.131G>T | p.Arg44Met | p.R44M | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TTL | SNV | Missense_Mutation | novel | c.968A>G | p.Glu323Gly | p.E323G | Q8NG68 | protein_coding | deleterious(0.04) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TTL | SNV | Missense_Mutation | rs746535633 | c.279N>T | p.Trp93Cys | p.W93C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TTL | SNV | Missense_Mutation | c.217N>T | p.Arg73Cys | p.R73C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTL | SNV | Missense_Mutation | c.414G>T | p.Lys138Asn | p.K138N | Q8NG68 | protein_coding | tolerated(0.13) | benign(0.163) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTL | SNV | Missense_Mutation | novel | c.661N>A | p.Leu221Ile | p.L221I | Q8NG68 | protein_coding | deleterious(0.03) | possibly_damaging(0.883) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TTL | SNV | Missense_Mutation | c.170N>T | p.Gly57Val | p.G57V | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTL | SNV | Missense_Mutation | c.679C>A | p.Pro227Thr | p.P227T | Q8NG68 | protein_coding | deleterious(0.02) | possibly_damaging(0.575) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTL | SNV | Missense_Mutation | rs780073175 | c.218N>A | p.Arg73His | p.R73H | Q8NG68 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |